Ocular allergy: Causes and therapeutic options

Clinical and Experimental Optometry

Volumn 83, Issue 5, 2000, Pages 257-270

  Schmid, Katrina L ^a   Schmid, Leisa M ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Antihistamines; Corticosteroids; Mast cell stabilisers; NSAIDs; Ocular allergy; Therapeutic pharmaceutical agents

Indexed keywords

EID: 0347267666     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2000.tb05014.x     Document Type: Article

References (81)

1. Howarth PH. Is aifergy increasing?Early life influences. Clin Exp Allergy 1998; 28: 2–7.
2. Davies RJ, Rusznak C, Devalia JL. Why is allergy increasing? Environmental factors. Clin Exp Allergy 1998; 28: 8–14.
3. Bartlett JD, Jaanus SD. Clinical Ocular Pharmacology, 3rd ed. Boston: Butterworth-Heinemann, 1995.
4. Palmares J, Delgado L. Ocular Allergy. Portugal: Medisa 1997.
5. Koevary SB. Ocular Immunlogy in Health and Disease. Boston: Butterworth-Heinemann, 1999.
6. Lockey RF, Bukantz SC. Allergens and Allergen Immunotherapy, 2nd ed. New York: Marcel Dekker, 1999.
7. Stock EL. Immunological mechanisms of allergic disease. Int Ophthalmol Clin 1988; 28: 262–266.
8. Hay SR. Immunological mechanisms of allergic eye disease. Clin Eye Vis Care 1999; 11: 21–24.
9. Forster CS. The pathophysiology of ocular allergy: Current thinking. Allergy 1995; 50: Supp121 6–9.
10. Hoffmann-Sommergruber K, Ferreira FD, Ebner C, Barisani T, Kominger L, Kraft D, Scheiner O, Baumgartner I. Detection of allergen-specific IgE in tears of grass pollen-allergic patients with allergic rhinoconjunc-tivitis. Clin Exp Allergy 1996; 26: 79–87.
11. Nomura K, Takamura E. Tear IgE concentrations in allergic conjunctivitis. Eye 1998; 12: 296–298.
12. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology, 3rd ed. Philadelphia: Saunders, 1997.
13. Akman A, Irkec M, Orhan M. Effects of lodoxamide, disodium cromoglycate and flurometholone on tear leukotriene levels in vernal keratoconjunctivitis. Eye 1998; 12: 291–295.
14. Butrus SI, Abelson MB. Laboratory evaluation of ocular allergy. Int Ophthalmol Clin 1988; 28: 324–328.
15. Trocme SD, Aldave AJ. The eye and the eosinophil. Surv Ophthalmol 1994; 39: 241–252.
16. Bacon AS, Tuft SJ, Metz DM, McGill JI, Buckley RJ, Baddeley S, Lightman SL. The origin of keratopathy in chronic allergic eye disease: A histopathological study. Eye 1993; 7 Suppl: 21–25.
17. Collin HB. Vernal and giant papillary conjunctivites. Part I. Vernal conjunctivitis. Aust J Optom. 1980; 63: 251–257.
18. Collin HB. Vernal and giant papillary conjunctivites. Part II. Suture induced conjunctivitis. Aust J Optom. 1981; 64: 4–8.
19. Collin HB. Vernal and giant papillary conjunctivites. Part III. Contact lens associated giant papillary conjunctivitis. Aust J Optom. 1981; 64: 71–76.
20. Friedlaender MH. Conjunctival provocative tests: A model of human ocular allergy. Trans Am Ophthal Soc 1989; 87: 577–597.
21. Donshik PC. Allergic conjunctivitis. Int Ophthalmol Clin 1988; 28: 294–302.
22. Friedlaender MH. Conjunctivitis of allergic origin: Clinical presentation and differential diagnosis. Surv Ophthalmol 1993; 38 Suppl: 105–114.
23. Abelson MB, George MA, Garofalo C. Deferential diagnosis of ocular allergic disorders. Ann Allergy 1993; 70: 95–109.
24. Buckley RJ. Allergic eye disease—A clinical challenge. Clin Exp Allergy 1998; 28 (Suppl 6): 39–43.
25. Udell IJ. Differential diagnosis of ocular allergy. Int Ophthalmol Clin 1988; 28: 275–281.
26. Jackson WB. Differentiating conjunctivitis of diverse origins. Surv Ophthalmol 1993; 38 Suppl: 91–104.
27. Buckley RJ. Vernal conjunctivitis. Int Ophthalmol Clin 1988; 28: 303–308.
28. Wong NN. Vernal vs. Atopic keratoconjunctivitis. Clin Eye Vision Care 1999; 11: 13–16.
29. Abu El-Asrar AM, Geboes K, Al-Kharashi SA, Al-Mosallam, AA, Tabbara KF, Al-Rajhi AA, Missotten L. An immunohistochemical study of collagens in trachoma and vernal keratoconjunctivitis. Eye 1998; 12: 1001–1006.
30. Tabbara KF. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol 1999; 34: 88–92.
31. Lazarou ZK. Contact lens associated giant papillary conjunctivitis. Clin Eye Vision Care 1999; 11:33–35.
32. Allansmith MR, Ross RN. Giant papillary conjunctivitis. Int Ophthalmol Clin 1988; 28: 309–316.
33. Friedlaender MH. Contact allergy and tox-icity in the eye. Int Ophthalmol Clin 1988; 28: 317–320.
34. Friedlaender MH. Management of ocular allergy. Ann Allergy Asthma Immunol 1995; 75: 212–224.
35. Friedlaender MH. Current concepts in ocular allergy. Ann Allergy 1991; 67: 5–10.
36. Jaanus SD. Ocular inflammatory disease: Pharmacologic update. Clin Eye Vision Care 1999; 11:3–12.
37. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: Immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993; 38 Suppl: 115–132.
38. Hingorani M, Lightman S. Therapeutic options in ocular allergic disease. Drugs 1995; 50: 208–221.
39. Gurwood AS. Understanding anti-allergy therapy. Br J Optom Disp 1999; 7: 99–107.
40. Butrus SI, Ochsner KI, Abelson MB, Schwartz LB. The level of tryptase in human tears. Ophthalmology 1990; 97: 1678–1683.
41. Soparkar CNS, Wilhelmus KR, Koch DD, Wallace GW, Jones DB. Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants. Arch Ophthalmol 1997; 115: 34–38.
42. Hill SJ. Distribution, properties and functional characteristics of three classes of his-tamine receptors Pharmacol Rev 1990; 42: 45–83.
43. Jaanus SD. Oral and topical antihistamines: Pharmacologic properties and therapeutic potential In ocular allergic disease. J Am Optom Assoc 1998; 69: 77–87.
44. Sharif NA, Su SX, Yanni JM. Emedastine: A potent, high affinity histamine Hl-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol 1994; 10: 653–664.
45. Dockhorn RJ, Duckett TG. Comparison of Naphcon-A and its components (naphazoline and pheniramine) in a provocative model of allergic conjunctivitis. Curr Eye Res 1994; 13: 319–324.
46. Parys W, Blockhuys S, Janssens M. New trends in the treatment of allergic conjunctivitis. Doc Ophthalmol 1992; 82: 353–360.
47. Heykants J, Van Peer A, Van de Velde V, Snoeck E, Meuldermans W, Woestenborghs R. The pharmacokinetic properties of topical levocabastine. Clin Pharmacokinet 1995; 29: 221–230.
48. Janssens M, Blockhuys S. Tolerability of levocabastine eye drops. Doc Ophthalmol 1993; 84: 111–118.
49. Abelson MB, Smith LM. Levocabastine. Evaluation in the histamine and compound 48/80 models of ocular allergy in humans. J Ophthalmol 1988; 95: 1494–1497.
50. Abelson MB, George MA, Schaefer K, Smith LM. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis. J Allergy Clin Immunol 1994; 94: 458–464.
51. Buscaglia S, Paolieri F, Catrullo A, Fiorino N, Riccio AM, Pesce G, Montagna P, Bagnasco M, Ciprandi G, Canonica GW. Topical ocular levocabastine reduced ICAM-1 expression on epithelial cells both In vivoand in vitro. Clin Exp Allergy 1996; 26: 1188–1196.
52. Søhoel P, Freng BA, Kramer J, Poppe S, Rebo R, Korsrud FR, Garud O, Woxen OJ, Olsen AK. Topical levocabastine compared with orally administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis. J Allergy Clin Immunol 1993; 92: 73–81.
53. Wihl JA, Rudblad S, Kjellén H, Blychert LA. Levocabastine eye drops versus sodium cromoglycate in seasonal allergic conjunctivitis. Clin Exp Allergy 1991; 21 Suppl 2: 37–38.
54. Abelson MB, George MA, Smith LM. Evaluation of 0.05% levocabastine, versus 4% sodium cromolyn in the allergen challenge model. Ophthalmology 1995; 102: 310–316.
55. Rimås M, Kjellman N-IM, Blychert L-O, Björkstén B. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests. Allergy 1990; 45: 18–21.
56. Vermeulen J, Mercer M. Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Pediatr Allergy Immunol 1994; 5: 209–213.
57. Goes F, Blockhuys S, Janssens M. Levocabastine eye drops in the treatment of vernal conjunctivitis. Doc Ophthalmol 1994; 87: 271–281.
58. Blaho K. AOA’s current trends in pharmacology and therapeutics histamine and antihistamine agents. J Am Optom Assoc 1993; 64: 586–588.
59. Allansmith MR, Ross RN. Ocular allergy and mast cell stabilisers. Surv Ophthalmol 1986; 30: 229–244.
60. Juniper EF, Guyatt GH, Ferrie PJ, King DK. Sodium cromoglycate eye drops: Regular versus ‘as needed’ use in the treatment of seasonal allergic conjunctivitis. J Allergy Clin Immunol 1994; 94: 36–43.
61. Leino M, Montan P, Njå F. A double-blind group comparative study of ophthalmic sodium cromoglycate 2% four times daily and 4% twice daily in the treatment of seasonal allergic conjunctivitis. Allergy 1994; 49: 147–151.
62. Ciprandi G, Buscaglia S, Catrullo A, Paolieri F, Riccio AM, Fiorino N, Cananica GW. Antiallergic activity of topical lodoxamide on in vivo and in vitro models. Allergy 1996; 51: 946–951.
63. Bonini S, Schiavone M, Bonini S, Magrini L, Lischetti P, Lambiase A, Bucci MG. Efficacy of lodoximide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Ophthalmology 1997; 104:849–853.
64. Capron M, Loiseau S, Papin JP, Robertson S, Capron A. Inhibitory effects of lodoxamide on eosinophil activation. Int Arch Allergy Immunol 1998; 116: 140–146.
65. Avunduk AM, Avunduk MC, Dayanir V, Tekelioglu Y, Dayioglu YS. Pharmacological mechanism of topical lodoxamide treatment in vernal keratoconjunctivitis: A flow-cytometric study. Ophthalmic Res 1998; 30: 37–43.
66. Richard C, Trinquand C, Bloch-Michel E, the Study Group Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Eur J Ophthalmol 1998; 8: 207–216.
67. Calonge N, Montero JA, Herreras JM, Juberías JR, Pastor JC. Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. Ann Allergy Asthma Immunol 1996; 77: 124–130.
68. Benbow AG, Eady R, Jackson D. The immunopharmacological actions of nedocromil sodium relative to the use of its 2% ophthalmic solution. Eye 1993; 7 Suppl: 26–28.
69. Bailey CS, Buckley RJ. Nedocromil sodium in contact-lens-associated papillary conjunctivitis. Eye 1993; 7 Suppl: 29–33.
70. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998; 81: 211–218.
71. Blaho K. Non-steroidal anti-inflammatory drugs: current trends in pharmacology and therapeutics. J Am Optom Assoc 1992; 63: 875–878.
72. Masferrer JL, Kulkarni PS. Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation. Surv Ophthalmol 1997; 41 (Supp 2): S35–S40.
73. Tauber J, Raizman MB, Ostrov CS, Laibovitz RA, Abelson MB, Betts JG, Koester JM, Gill D, Schaich L. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Oc Pharmacol Therapeut 1998; 14: 137–145.
74. Raizman MB. Results of a survey of patients with ocular allergy treated with topical ketorolac tromethamine. Clin Therapeut 1995; 17: 882–890.
75. Johnson D, Gottanka J, Flügel C, Hoffman F, Futa R, Lütjen-Drecoll E. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol 1997; 115: 375–383.
76. Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic con-junctivitis. Am J Ophthalmol 1997; 123: 791–797.
77. Shulman DA, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1999: 106: 362–369.
78. Lehmann R, Assil K, Steward R, Fox K. Comparison of rimexolone 1% ophthalmic suspension to placebo in control of postcataract surgery inflammation. Invest Ophthalmol Vis Sci (Suppl) 1995; 36: S793.
79. Wong LC, Wong NN, Lazarou ZK. Non-traditional therapies for vernal and atopic keratoconjunctivitis. Clin Eye Vis Care 1999; 11: 17–20.
80. Nehmad L. Recent developments in ocular allergy. Clin Eye Vis Care 1999; 11: 37–39.
81. Friedlaender MH. The current and future therapy of allergic conjunctivitis. Curr Opinion Ophthalmol 1998; 9: 54–58.